1-ethyl-4-(trifluoromethyl)-1H-imidazole | 81769-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-ethyl-4-(trifluoromethyl)-1H-imidazole
• 英文别名: 1-ethyl-4-(trifluoromethyl)imidazole
• CAS: 81769-72-4
• 化学式: C₆H₇F₃N₂
• 分子量: 164.13
• InChiKey: MBDFZQKKFSXXQK-UHFFFAOYSA-N

物化性质

• 沸点：
  213.5±35.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-(trifluoromethyl)-1H-imidazole 在 甲醇 、 sodium tetrahydroborate 、 四(三苯基膦)钯 、 正丁基锂 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 水 为溶剂， 反应 34.5h， 生成 (4-(1-ethyl-4-(trifluoromethyl)-1H-imidazol-2-yl)-3-fluorophenyl)methanol
  参考文献：
  名称：

  WO2020132269A5

  摘要：

  公开号：

  WO2020132269A5
• 作为产物：
  描述：

  1-乙基咪唑 、 三氟碘甲烷 、 甲醇 以4%的产率得到
  参考文献：
  名称：

  KIMOTO, HIROSHI;FUJII, SHOZO;COHEN, L. A., J. ORG. CHEM., 1982, 47, N 15, 2867-2872

  摘要：

  DOI：

文献信息

• FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zeng Qingping

  公开号：US20110263647A1

  公开（公告）日：2011-10-27

  The invention relates to thiazole compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种式I的噻唑化合物及其组合物，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途，其中变量具有本文所提供的定义。本发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢紊乱有关的疾病状态中使用此类噻唑化合物和其组合物的治疗用途。
• Photochemical perfluoroalkylation of imidazoles
  作者：Hiroshi Kimoto、Shozo Fujii、Louis A. Cohen

  DOI：10.1021/jo00136a010

  日期：1982.7
• PSEUDOBASE BENZO[C]PHENANTRIDINES WITH IMPROVED EFFICACY, STABILITY AND SAFETY
  申请人：Shaw Kenneth

  公开号：US20100256164A1

  公开（公告）日：2010-10-07

  Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula I are provided herein. The variables R, R 1 , R 2 , R 3 , and R 4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and/or topoisomerase II modulation are also provided.
• SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
  申请人：KSQ Therapeutics Inc.

  公开号：US20210115049A1

  公开（公告）日：2021-04-22

  The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X 1 , X 2 , X 11 , X 12 , R 1 , R 3 , R 5 , R 5′ , R 6 , and R 7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
• US8362028B2
  申请人：——

  公开号：US8362028B2

  公开（公告）日：2013-01-29